Compare Eli Lilly And Co (LLY) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs VanEck Rare Earth/Strategic Metals — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while VanEck Rare Earth/Strategic Metals trades at $60.97 (market cap $1.75B). The key difference: Eli Lilly And Co is far larger — about 594.3× VanEck Rare Earth/Strategic Metals's market cap, and Eli Lilly And Co pays a 0.59% dividend while VanEck Rare Earth/Strategic Metals pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and VanEck Rare Earth/Strategic Metals for 50 Days on average.
| LLY | REMX | |
|---|---|---|
Market Cap | $1.04T | $1.75B |
Volume | 3,064,878 | 930,523 |
Sector | Health | Sector/Thematic |
52-Week High | $1.28K | $109.53 |
52-Week Low | $799.57 | $60.58 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $60.58, down 2.1% with a bearish technical outlook. The ETF shows high volatility and faces pressure from rare earth market dynamics. Recent news highlights geopolitical tensions around critical minerals and China's export controls, while institutional interest includes Bank of America increasing its stake by 72.1% in Q2 2026 (SEC filing, August 2026).
Outlook remains cautious due to sector volatility and China dependency risks. Investment appeal lies in strategic positioning for supply chain independence, but high turnover and exposure fluctuations warrant careful risk assessment. Key catalysts include U.S. policy developments and rare earth supply chain expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
